About Rubicon Research Ltd
Rubicon Research Limited is an integrated pharmaceutical company that specializes in the research, development, and production of pharmaceutical products, with a focus on innovation and regulated markets such as the United States. Established in 1999 under the name Rubicon Consultants Private Limited, the company underwent multiple name changes and structural transitions, converting to a Public Limited Company in July 2024. Rubicon has GMP-certified manufacturing facilities in Ambernath and Satara, Maharashtra, and began producing specialized drugs at its Ambernath facility in 2011.
The company has actively pursued strategic acquisitions to expand its operational scope and market reach. Key acquisitions include Meditab Specialities Limited in 2021 and Validus, a US-based marketer of branded formulation products, in 2024. Validus contributes two CNS therapy products, Equetro and Marplan, to Rubicon’s portfolio. These acquisitions, alongside the company's specialty and drug-device combination products, demonstrate its commitment to innovation and growth in high-value therapeutic areas.
Rubicon is backed by prominent investors such as General Atlantic Singapore RR Pte. Ltd., which acquired a majority stake in 2019. The company is looking to raise Rs 1,085 Crores through its Initial Public Offering (IPO), split between a Rs 500 Crore Fresh Issue and Rs 585 Crore via Offer for Sale. This funding is intended to support further innovation and expansion of its pharmaceutical operations, particularly in regulated international markets.
Traders may find Rubicon Research Limited appealing due to its robust research-driven approach, strategic acquisitions in high-growth segments, and its focus on regulated markets like the US. Its IPO presents an opportunity for investors to engage with a company positioned for growth and diversification in the pharmaceutical sector. Founded 1999
Headquarters Thane (West)
